<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 03, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323761</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-540-5821</org_study_id>
    <nct_id>NCT04323761</nct_id>
  </id_info>
  <brief_title>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection</brief_title>
  <official_title>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to provide expanded access of remdesivir (RDV) for the
      treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>SARS-CoV2 Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Intravenous infusion administered over a 30 to 120 minute period</description>
    <other_name>GS-5734™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent, or with a legal representative
             who can provide informed consent, or enrolled under International Conference on
             Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the
             investigator (participants ≥ 18 years of age)

          -  Hospitalized with confirmed SARS-CoV2 by polymerase chain reaction (PCR) or known
             contact of confirmed case with syndrome consistent with coronavirus disease (COVID-19)
             with PCR pending

          -  Requiring invasive mechanical ventilation (e.g., via endotracheal intubation or
             tracheostomy)

          -  Adequate renal function with estimated glomerular filtration rate (eGRF) ≥ 30 ml/min
             by local laboratory measure

          -  Alanine aminotransferase (ALT) ≤ 5 x upper limit of normal (ULN) by local laboratory
             measure

        Exclusion Criteria:

          -  Evidence of multiorgan failure

          -  Pressor requirement to maintain blood pressure

          -  Renal failure (eGRF &lt; 30 mL/min or dialysis or continuous Veno-Venous Hemofiltration)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health - JFK Medical Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai South Nassau</name>
      <address>
        <city>Oceanside</city>
        <state>New York</state>
        <zip>11572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

